Practical guides
26 cited guides covering reconstitution math, compound-by-compound evidence, and the questions dosing charts never answer. Every page names its author and medical reviewer, reports what published studies actually used, and never recommends a dose.
Looking for deep-dive monographs instead? See the research library and peptide profiles, or run the numbers in interactive tools.
The arithmetic and sterile technique behind measuring a clinician-prescribed dose.
Reconstitution is arithmetic plus sterile technique: vial amount ÷ diluent volume = concentration; clinician-prescribed dose ÷ concentration = draw volume.
Medically reviewed · 2025-06-20 · by Daniel Reyes
Bacteriostatic water is sterile water with 0.9% benzyl alcohol, which suppresses bacterial growth across multiple vial punctures — the reason it is standard for multi-dose reconstitution.
Medically reviewed · 2025-06-20 · by Daniel Reyes
The bac-water volume you add sets the concentration — and therefore how readable your syringe graduations are. Three worked examples show the trade-offs.
Medically reviewed · 2025-06-20 · by Daniel Reyes
Peptide-peptide compatibility in a shared syringe is essentially unstudied. Pharmacy science treats co-mixing as an open stability question — forums treat it as a convenience.
Medically reviewed · 2025-06-20 · by Daniel Reyes
Three inputs, two divisions, one hard boundary: a peptide calculator may convert a prescribed dose into syringe units — and must never invent the dose.
Medically reviewed · 2025-06-20 · by Daniel Reyes
What the rodent literature actually used, where chart numbers come from, and what remains unproven in humans.
Every BPC-157 dosing number circulating online extrapolates from rodent studies. Here is what those studies actually used, and why that is not a human protocol.
Medically reviewed · 2025-06-20 · by Daniel Reyes
Deconstructing the ubiquitous BPC-157 dosing chart: the rodent study behind it, the allometric-scaling problem, and what a 200-lb male row really represents.
Medically reviewed · 2025-06-20 · by Daniel Reyes
Injection, oral solution, and capsules have different evidence trails in the BPC-157 literature. What each route showed in animals — and what none has shown in humans.
Medically reviewed · 2025-06-20 · by Daniel Reyes
Oral BPC-157 has rodent gut-model support; injectable has rodent soft-tissue support. Neither has human outcome trials. Route determines which claims are even plausible.
Medically reviewed · 2025-06-20 · by Daniel Reyes
The popular 4–8 week "cycle" convention maps loosely to rodent study durations — not to any human washout or safety data. Here is the honest timeline picture.
Medically reviewed · 2025-06-20 · by Daniel Reyes
The rat Achilles data behind the tendon-repair reputation: what improved, by how much, through what mechanism — and the human trial that still does not exist.
Medically reviewed · 2025-06-20 · by Daniel Reyes
CJC-1295, Ipamorelin, MK-677 — the trials that exist, the programs that failed, and the stack claims.
The Drug Affinity Complex gives CJC-1295 a ~6–8 day half-life and multi-day GH/IGF-1 elevation. The same property is its biggest safety question.
Medically reviewed · 2025-06-20 · by Daniel Reyes
Ipamorelin earned its "clean" reputation by sparing cortisol and prolactin. Its largest human trial still failed. Both facts matter.
Medically reviewed · 2025-06-20 · by Daniel Reyes
GHRH-receptor plus ghrelin-receptor agonism is real synergy at the pituitary. Combined human outcome trials of this pairing: zero.
Medically reviewed · 2025-06-20 · by Daniel Reyes
MK-677 has something rare in this space: year-long randomized human data. It raised GH and lean mass in older adults — alongside appetite, edema, and blood glucose.
Medically reviewed · 2025-06-20 · by Daniel Reyes
TB-500 and GHK-Cu: route-by-route evidence and the regulatory status behind each.
TB-500 is a synthetic fragment of thymosin beta-4 with animal-model repair data, a racehorse-doping past, and zero published human trials of the sold fragment.
Medically reviewed · 2025-06-20 · by Daniel Reyes
A TB-500 calculator can convert a prescribed dose into a draw volume. It cannot generate the dose — for TB-500 no human dose exists to generate.
Medically reviewed · 2025-06-20 · by Daniel Reyes
Topical GHK-Cu has controlled cosmetic studies behind it. Injectable GHK-Cu borrows that credibility with almost nothing of its own.
Medically reviewed · 2025-06-20 · by Daniel Reyes
Semaglutide and AOD-9604 — the strongest and weakest evidence trails in the space, side by side.
STEP-trial weight loss near 15%, cardiovascular outcome data, a boxed warning, and an FDA-warned compounded gray market: the full semaglutide picture.
Medically reviewed · 2025-06-20 · by Maya Okafor
Sublingual semaglutide drops are compounded products with no published outcome trials. The approved oral tablet needed an absorption enhancer for a reason.
Medically reviewed · 2025-06-20 · by Maya Okafor
AOD-9604 is the lipolytic fragment of growth hormone (hGH 177-191). It reached human obesity trials — and its development ended when efficacy did not hold up.
Medically reviewed · 2025-06-20 · by Daniel Reyes
Unusually for a research peptide, AOD-9604 has real human dosing history — oral, daily, across a wide range — from trials that then failed on efficacy.
Medically reviewed · 2025-06-20 · by Daniel Reyes
Timing, stacking, sex-specific data, and a one-page compound reference.
A one-page reference: regulatory status, evidence grade, studied endpoints, and key risks for every major research peptide — with links to full guides.
Medically reviewed · 2025-06-20 · by Daniel Reyes
GH-axis timing rules trace to real physiology (insulin blunts GH release; pulses cluster in early sleep). Most other peptide timing rules trace to nothing.
Medically reviewed · 2025-06-20 · by Maya Okafor
Most peptide research enrolled male animals or male-heavy cohorts. What that gap means for women — plus the contraindications that apply specifically.
Medically reviewed · 2025-06-20 · by Maya Okafor
Every added compound multiplies unknowns: no combination trials exist for any popular stack, interactions are unstudied, and attribution becomes impossible.
Medically reviewed · 2025-06-20 · by Daniel Reyes
The standard every guide must meet is public: editorial policy · corrections policy
